索拉非尼联合TACE对晚期肝癌患者肝功能及血清VEGF水平的影响  

Effects of sorafenib combined with TACE on liver function and serum VEGF level in patients with advanced liver cancer

作　　者：陈泳松 王德芬 CHEN Yongsong;WANG Defen(the First People's Hospital of Ziyang City,Ziyang,Sichuan 641300,China)

机构地区：[1]四川省资阳市第一人民医院,641300

出　　处：《重庆医学》2022年第S01期45-47,共3页Chongqing medicine

摘　　要：目的探讨罹患晚期肝癌患者在肝动脉化疗栓塞(TACE)治疗基础上联用索拉非尼的效果及对肝功能指标和血清血管内皮生长因子(VEGF)水平的影响。方法选择2017年6月至2019年6月该院收治的晚期肝癌患者50例,随机分为观察组和对照组,每组25例。对照组单纯采用TACE方案治疗,观察组在TACE方案治疗基础上加用索拉非尼。对比两组患者总有效率、肝功能指标(包括总胆红素和谷丙转氨酶)、肿瘤血管新生指标(包括VEGF和基质金属蛋白酶)、不良反应发生率及2年生存率。结果观察组患者总有效率明显高于对照组,差异有统计学意义(P<0.05);两组患者治疗前肝功能指标比较,差异均无统计学意义(P>0.05);两组患者治疗后各项肝功能指标均上升,但观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。两组患者治疗前各项肿瘤血管新生指标比较,差异均无统计学意义(P>0.05);两组患者治疗后各项肿瘤血管新生指标均降低,观察组患者降低更为明显,差异均有统计学意义(P<0.05)。两组患者给药过程中不良反应发生率比较,差异均无统计学意义(P>0.05)。观察组患者2年生存率明显高于对照组,差异有统计学意义(P<0.05)。结论针对罹患晚期肝癌的患者在TACE基础上联用索拉非尼可提高临床疗效,减轻肝功能损伤,抑制肿瘤新生血管生成,且具有较高的安全性,并可提升患者2年生存率。Objective To investigate the effect of sorafenib and its effect on hepatic function index and serum VEGF levels based on percutaneous hepatic artery chemoembolization(TACE).Methods We selected 50 patients with advanced liver cancer from June 2017 to June 2019,randomly grouped,25 patients treated with TACE alone and 25 patients with sorafenib and compared with the two groups with total efficiency,liver function index,tumor angiogenesis index,adverse reaction rate and 2-year survival rate.Results The total efficiency of the observation group was 60.00%,32.00%higher than the control group(P<0.05).In the two groups,liver function indicators,total bilirubin(TBIL),alanine amino transferase(ALT)were detected without difference(P>0.05),which increased after unfolding,but the observed group was lower than controls(P<0.05).When the two groups showed no difference in the tumor angiogenesis index,serum vascular endothelial growth factor(VEGF),matrix metalloproteinase(MMP-9,P>0.05),each index decreased and the decrease was more significant in the observation group(P<0.05).There was no significant difference in the ADR rates during administration(P>0.05)and the 2-year survival was higher in the observed group than in the control group(P<0.05).Conclusion For patients with advanced liver cancer,the combination of sorafenib based on TACE can improve the clinical effect,reduce liver function damage,inhibit tumor neoangiogenesis,have high safety,and improve the 2-year survival rate.

关 键 词：晚期肝癌 TACE 索拉非尼 肝功能 血清VEGF 生存率 

分 类 号：R73[医药卫生—肿瘤]